The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers

Sepsis, a dysfunctional immune response to infection leading to life-threatening organ injury, represents a significant global health issue. Neonatal sepsis is disproportionately prevalent and has a cost burden of 2-3 times that of adult patients. Despite this, no widely accepted definition for neon...

Full description

Bibliographic Details
Main Authors:	Emily Hensler, Habesha Petros, Chyna C. Gray, Chun-Shiang Chung, Alfred Ayala, Eleanor A. Fallon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Immunology
Subjects:	sepsis neonate checkpoint inhibitor PD-1 PD-L1 VISTA
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.940930/full

Similar Items

Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis
by: Eleanor A. Fallon, et al.
Published: (2017-11-01)

Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes
by: Medine Dicleli, et al.
Published: (2024-03-01)

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2023-12-01)

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2024-01-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
by: Dia Roy, et al.
Published: (2023-10-01)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
by: Nour el Imane Issam Salah, et al.
Published: (2023-08-01)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
by: Giandomenico Roviello, et al.
Published: (2020-10-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-03-01)

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma
by: Aida Jlassi, et al.
Published: (2024-04-01)

Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
by: Paulina Chmiel, et al.
Published: (2023-06-01)

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
by: Liru Wang, et al.
Published: (2018-09-01)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
by: Florian Huemer, et al.
Published: (2020-04-01)

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer
by: Yifan Cao, et al.
Published: (2024-02-01)

Preliminary analysis of immune-related markers in thymic carcinoid
by: Jiaqi Zhang, et al.
Published: (2023-12-01)

Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells
by: Rafał Pęksa, et al.
Published: (2022-07-01)

VISTA, PDL-L1, and <i>BRAF</i>—A Review of New and Old Markers in the Prognosis of Melanoma
by: Andreea Cătălina Tinca, et al.
Published: (2022-01-01)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
by: Shuxin Huang, et al.
Published: (2022-11-01)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
by: Rita Terenziani, et al.
Published: (2021-06-01)

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
by: Aly-Khan A. Lalani, et al.
Published: (2018-01-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
by: Reid P. Bissonnette, et al.
Published: (2021-08-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
by: Michelle E. Wakeley, et al.
Published: (2023-05-01)

Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes
by: Rafał Pęksa, et al.
Published: (2021-04-01)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
by: Jun Gong, et al.
Published: (2019-03-01)

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
by: Simona Serratì, et al.
Published: (2022-01-01)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
by: Charissa A. C. Jessurun, et al.
Published: (2017-09-01)

PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
by: Quentin Wright, et al.
Published: (2021-07-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
by: Federica Costa, et al.
Published: (2018-09-01)

Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
by: Elissavet Ntemou, et al.
Published: (2024-03-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Establishment of an Ex Vivo Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma
by: Shanjuan Hong, et al.
Published: (2022-04-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model
by: Yi-Ru Pan, et al.
Published: (2020-11-01)

Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer
by: Kriti Jain, et al.
Published: (2023-01-01)

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
by: Michael Kuske, et al.
Published: (2022-03-01)

Tumour-immune dynamics with an immune checkpoint inhibitor
by: Elpiniki Nikolopoulou, et al.
Published: (2018-06-01)

The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer
by: Juan He, et al.
Published: (2021-07-01)